ifa systems AG

  • WKN: 783078
  • ISIN: DE0007830788
  • Land: Deutschland

Nachricht vom 24.06.2019 | 21:33

Major order for subsidiary of ifa systems AG

DGAP-News: ifa systems AG / Key word(s): Incoming Orders/Change in Forecast

24.06.2019 / 21:33
The issuer is solely responsible for the content of this announcement.


Major order for subsidiary of ifa systems AG

  • License agreement about EUR 1.6 million to use Inoveon's database worldwide and non-exclusively for research purposes
  • One-time effect will raise the guidance for 2019

Inoveon Corporation, a US American subsidiary of ifa systems AG, has entered into a license contract in the amount of USD 1.75 million (EUR 1.6 million). This contract grants a company that wishes to remain anonymous the worldwide non-exclusive license for access to 3 million de-identified and ETDRS graded ophthalmological images produced by Inoveon Corporation. The one-time license fee will be paid in the current fiscal half year and thereby have a positive impact on the sales and profit situation of ifa systems group in the fiscal year 2019. Therefore, the Management Board will revise the guidance for the revenue and result after the first half of the year.

"We are pleased to have found additional prospects for the full database who can successfully use the data for research purposes", says Joerg Polis, chairman of the Management Board of ifa systems AG. "Previous attempts to develop a business model for the database were narrow in scope and failed, for example on the question of how to build a payable usage model for the database." Licensing the full database for specific analysis has resulted in the highest and best use as indicated by past and current license arrangements. Among other licensors, Topcon Corporation, the previous majority shareholder, recently also licensed the Inoveon database for an undisclosed amount.

The revenue and earnings contribution resulting from this license agreement is a one-off effect and therefore was not included in the planning for the financial year. The guidance for the financial year will therefore be revised after the first half-year. "Our business has developed successfully in the first months of the year partly due to the implementation of the telematics infrastructure", says Polis. "This extraordinary order is equivalent to more than 20 percent of the planned revenue and will have a significant on-off impact on the earnings situation. Thus, we want to update our guidance for the financial year 2019 with the half-year report." In accordance with the priorities for the current financial year, the Management Board plans to use the additional liquid funds to further reduce external debt and to invest to a greater extent in product development.

Dates:

The half-year report is expected to be published on August 15, 2019.

Contact for information:
ifa systems AG
Augustinusstr. 11b
50226 Frechen (Germany)
ir@ifasystems.de
+49 2234 933 670

 



24.06.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Anleihe im Fokus

„Semper idem Underberg AG: Emission neuer Unternehmensanleihe 2019/2025“

- Emissionsvolumen: bis zu 60 Mio. Euro
- Anleihenumtausch: 23.010. bis 06.11.2019
- Neuzeichnung: 07.11. bis 12.11.2019
- ISIN: DE000A2YPAJ3 / WKN: A2YPAJ
- Stückelung / Mindestanlage: 1.000 Euro
- Zinssatz (Kupon):
Liegt in einer Spanne von 4,00 % bis 4,25 % p.a.
- Laufzeit: 6 Jahre
- Zinszahlung: jährlich, jeweils am 18. November (nachträglich), erstmals am 18. November 2020
- Rückzahlungskurs: 100%
- Fälligkeit: 18. November 2025
- Listing: Listing im Freiverkehr (Open Market) der Frankfurter Wertpapierbörse vorgesehen

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

News im Fokus

Continental AG: Continental AG berücksichtigt im dritten Quartal 2019 nicht zahlungswirksame Wertminderungen und Restrukturierungsrückstellungen

22. Oktober 2019, 13:34

Aktuelle Research-Studie

CO.DON AG

Original-Research: CO.DON AG (von Sphene Capital GmbH): Buy

21. Oktober 2019